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Abstract
Viral infections activate the powerful interferon (IFN) response that induces the expression of several hundred IFN stimulated 
genes (ISGs). The principal role of this extensive response is to create an unfavourable environment for virus replication and 
to limit spread; however, untangling the biological consequences of this large response is complicated. In addition to a seem-
ingly high degree of redundancy, several ISGs are usually required in combination to limit infection as individual ISGs often 
have low to moderate antiviral activity. Furthermore, what ISG or combination of ISGs are antiviral for a given virus is usually 
not known. For these reasons, and since the function(s) of many ISGs remains unexplored, genome- wide approaches are well 
placed to investigate what aspects of this response result in an appropriate, virus- specific phenotype. This review discusses 
the advances screening approaches have provided for the study of host defence mechanisms, including clustered regularly 
interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9), ISG expression libraries and RNA interfer-
ence (RNAi) technologies.
INTRODUCTION
As obligate intracellular pathogens, viruses rely on host 
machinery to complete their replicative cycle; virus–host 
interactions are therefore crucial to the infectivity of the 
virus particle and its ability to cause disease [1]. Whilst there 
are host dependency factors present in cells that permit the 
replication of viruses, there are also antiviral factors that 
restrict the pathogen’s ability to replicate [2]. Despite many 
viruses encoding countermeasures to these antiviral factors 
[3], our understanding of them is pivotal to understanding 
their weaknesses and aids our understanding of how infection 
can be controlled.
Upon encountering a pathogen, the innate immune response 
is activated and subsequently triggers adaptive immunity. A 
component of the innate immune response, the evolutionarily 
conserved interferon (IFN) system [4], has well- established 
antiviral defence roles. This response slows viral replication 
and the rate at which infection spreads before activation of 
the adaptive immune response [5, 6]. Furthermore, IFNs are 
important immunomodulatory cytokines that regulate the 
magnitude of the host response and therefore limit tissue 
damage [7].
All cells express pathogen recognition receptors (PRRs) that 
upon recognition of pathogen- associated molecular patterns 
(PAMPs), generally consisting of viral nucleic acids upon 
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leading to the production of cytokines, including IFN [8]. 
There are three families of IFN, type I, II and III. Whilst type 
II IFN (IFN-γ) regulates the cell- mediated response to infec-
tion, type I IFN, consisting of 13 subtypes including IFN-α 
and IFN-β, and type III IFN (IFN-λ) establish an antiviral 
state in both the infected cell and surrounding, non- infected 
cells [7, 9, 10]. Secreted IFN binds to cell surface receptors 
and initiates a canonical signalling cascade dependent on 
the Janus kinase (JAK)–signal transducer and activator of 
transcription (STAT) pathway. Activation of the JAK–STAT 
pathway results in the production of hundreds of interferon 
stimulated genes (ISGs) culminating in extensive biological 
effects (reviewed by Fensterl et al. [6]).
Untangling the biological consequences of this large physi-
ological response is complicated. Many ISGs have broad 
antiviral activity, such as double- stranded RNA (dsRNA)- 
dependent protein kinase R (PKR) that induces a shutdown of 
general protein translation upon activation and phosphoryla-
tion of eukaryotic translation initiation factor 2A (eIF2A), and 
the 2′,5′-oligoadenylate synthetase (OAS)–RNase L pathway 
that degrades single- stranded RNAs (ssRNAs), including 
mRNAs of viral and cellular origin [11, 12]. Others, such as 
IFN- induced protein with tetratricopeptide repeats (IFIT) 
and IFN- induced transmembrane (IFITM) proteins inhibit 
specific viruses, but many viruses remain insensitive to them. 
Because IFN signalling causes an extensive physiological reac-
tion, many ISGs play critical regulatory roles that temper the 
response and prevent autoinflammatory disease and excessive 
tissue damage. For these reasons, and since the function(s) of 
many ISGs remains unexplored, genome- wide approaches are 
well placed to investigate which aspects of this broad response 
results in an appropriate, virus- specific antiviral phenotype.
Advances in molecular tools enabling genome-wide 
approaches
Advances in molecular tools have transformed our ability to 
investigate virus–host interactions and facilitated the use of 
genome- wide genetic screening in the field. The development 
of next- generation sequencing (NGS) and genome editing 
tools have enabled sequence- based analysis with improved 
output reliability [13, 14]. These tools have not only allowed 
for specific targeting of genes but make anticipated pheno-
typic expression more easily interpretable [13, 15]. Due to the 
nature of genetic screening, the ability to reliably characterise 
genes that produce the desired output is paramount.
Whilst previous studies investigating virus–host interactions 
have been limited to investigating a single to a few genes at 
a time, screening platforms are a high- throughput method 
allowing for the identification of many genes. This lends 
itself to the study of broad signalling systems, such as the 
IFN response, by identifying complex network interactions 
that work in concert. Genome- wide genetic screening has 
widely been used to investigate virus–host interactions, as 
will be further discussed, and up to the date of publication, 
many of these screens have identified host dependency factors 
in the cell required for successful virus replication [16–21]. 
These screens have also been used to identify antiviral factors 
(Fig. 1).
As mentioned, the IFN response results in the production of 
hundreds of ISGs [6]. This is a largely redundant response 
as it is expected that only a small number of these proteins 
will significantly contribute to the antiviral response. Instead, 
there are many ISGs which have minor effects on viral repli-
cation resulting in a synergistic effect. However, which of 
the hundreds of ISGs are antiviral for which virus is mostly 
unknown and finding the associated restriction factor could 
be likened to finding a needle in a haystack. Results from 
previous work have indicated that mice defective in a broad- 
ranging ISG, such as PKR or OAS, are still able to produce 
an antiviral response indicating that several factors are likely 
to be at play [2, 22]. The question then becomes; if several 
ISGs each play a modest role [23], how are functional compo-
nents of this vast redundant response identified without an 
overarching phenotype? Genome- wide genetic screening 
has the ability to identify novel genes and exclude genes not 
involved in the antiviral response, due to its high- throughput 
nature and size of gene libraries available, therefore aiding the 
identification of redundant genes in the response. Subsequent 
comparative analysis of validated genes can identify whole 
pathways involved in virus–host interactions; something not 
possible in single- gene studies [24, 25].
Screening platform design
Screens, either RNA interference (RNAi), clustered regularly 
interspaced short palindromic repeats/CRISPR associated 
protein 9 (CRISPR/Cas9) or overexpression, are performed in 
an arrayed or pooled format in which the genetic perturbators 
are arranged individually in multi- well plates or are cloned 
to create a library respectively. Each screening platform has 
advantages and disadvantages. Arrayed libraries are preferred 
for experimental designs investigating a number of pheno-
types or with small culture volumes [13]. They permit plate 
reader screening [26, 27], allowing individual wells to be 
treated with drug compounds, infected with a pathogen or 
put under environmental stress. Conversely, pooled screening 
allows for quantification of constructs within a population 
whilst being less expensive and labour intensive [13]. It is also 
possible to split pools into several smaller pools allowing for 
the comparison of two or more populations by microarray 
or NGS.
There are three primary readouts of screens; multi- well plate 
readers [26, 27], microscopy [28] or flow cytometry [29, 30]. 
A problem however with using microscopy to investigate 
virus- host interactions is the variability in results. Previous 
studies have yielded varying results dependent on if a host cell 
component indicative of infection is imaged or if infection is 
monitored using a reporter virus, such as GFP [31].
CRISPR/CAS9 SCREENING
Genome- wide CRISPR/Cas9 knockout screening utilises 
clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR associated protein 9 (Cas9) genome 
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editing; first described to target and cleave the human 
genome in 2013 to introduce loss- of- function muta-
tions [32–35]. In CRISPR/Cas9 loss- of- function genetic 
engineering, the Cas9 enzyme is programmed with a 
single guide RNA (sgRNA) complementary to the gene 
of interest and upon complementary binding, site specific 
DNA cleavage results in a double strand break (DSB). In 
the absence of a homologous sequence, the DSB is repaired 
via non- homologous end joining (NHEJ); an error- prone 
process resulting in insertions and deletions (INDELS). 
This mechanism is exploited in genome engineering as 
the resulting frameshift mutations disrupt gene function 
(reviewed elsewhere [36, 37]). CRISPR/Cas9 screening 
utilises this technology in a high- throughput manner to 
provide an experimental design that works in a phenotype- 
to- genotype direction [13, 15]. This forward screening 
approach allows the identification of unexpected genes 
involved in virus- host interactions that are unlikely to 
be identified through hypothesis- based reverse genetic 
screening approaches.
Pooled screening introduces a library of sgRNAs either 
alongside Cas9 or into Cas9- expressing cells primarily via 
lentiviral transduction at a low multiplicity of infection 
(MOI) in order to reduce multiple vector uptake by cells; 
other delivery methods include PiggyBac transposons [38] 
and adeno- associated virus (AAV) delivery [39]. This results 
in permanent modification and complete knockout of the 
targeted gene. A selection pressure is then applied to select 
for successfully transduced cells and an assay is required to 
separate cells with the phenotype of interest. Genomic DNA is 
harvested and sgRNA isolated and amplified for NGS. Enrich-
ment significance is then calculated for each sgRNA isolated 
(detailed protocols have been published previously [40, 41]).
Fig. 1. Antiviral factors identified using screening methods. A schematic illustrating a selection of antiviral factors identified during 
genome- wide screening. Each antiviral factor is attributed to a stage in the viral life cycle corresponding to literature references 
throughout this review [52, 53, 63, 65, 69, 85, 87, 141]; it should be noted that many ISGs have been seen to act at additional stages. The 
key indicates the screening type used to identify each example: (c), clustered regularly interspaced short palindromic repeats/CRISPR 
associated protein 9 (CRISPR/Cas9), (o), Overexpression, (r), RNA interference (RNAi). Abbreviations used: HCV; Hepatitis C Virus, 
SARS- CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2, IAV; Influenza A Virus, HIV; Human Immunodeficiency Virus, HCMV; 
Human Cytomegalovirus, EBOV; Ebola Virus, YFV; Yellow Fever Virus, DENV; Dengue Virus, ZIKV; Zika Virus, WNV; West Nile Virus, BUNV; 
Bunyavirus. Created with biorender.combiorender.com.
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Alternative strategies in CRISPR/Cas9 screening 
experimental design
Pooled screens can be negative or positive screens. Negative 
screens work through performing NGS at both the beginning 
and end of applying the selection pressure and identifying 
sgRNAs that have been depleted; these targeted genes are 
therefore critical to cell proliferation and survival. Conversely, 
positive selection screens require only a single round of NGS. 
However, it should be noted that most protocols involve 
sequencing at the beginning and end to control for factors 
such as enrichment that occur prior to infection with the 
pathogen of interest. Following application of the selection 
pressure, cells that have survived are sequenced and enriched 
sgRNAs correspond to target genes whose knockout leads to 
cell survival or that ordinarily restrict cell growth, such as 
tumour suppressor genes. Screens can also be performed with 
a reporter- based assay. These are followed by fluorescence 
activated cell sorting (FACS) enrichment of cells expressing 
sgRNAs rather than enrichment by cell growth or viability 
[42, 43]. Negative screening tends to be used to identify essen-
tial genes and genes required for transformation by oncogenic 
viruses such as Epstein Barr virus (EBV) or in cancer, whereas 
positive screens are used to identify resistance to toxins or 
pathogen infections [13].
Of the many genome- wide pooled sgRNA knockout libraries 
available for the human genome, two have been predomi-
nantly adopted; the activity- optimised genome- wide library 
by Sabatini and Lander which has 10 sgRNAs per gene and 
187535 sgRNAs in total [44] and GeCKOv2 by Zhang et al. 
which has 6 sgRNAs per gene and 123411 sgRNAs in total 
[45]. Two second generation libraries have subsequently 
been designed to optimise the specificity of the sgRNAs. 
These are the Toronto KnockOut library by Moffat which 
has 12 sgRNAs/ gene and 176500 sgRNAs in total [46] and 
the Brunello genome- wide library by Doench et al. which 
has 76441 sgRNAs in total with four sgRNAs/ gene [47]. The 
ability to design custom sgRNA libraries for a selected gene 
set is also available. This allows focused screens within an area 
of interest; for example, the antiviral response, which will be 
further discussed.
Alongside the CRISPR/Cas9 system for creating knockouts, 
a catalytically dead version of Cas9 (dCas9) has been devel-
oped which can be used for CRISPR activation (CRISPRa) 
and CRISPR interference (CRISPRi) (Fig.  2). dCas9 is 
programmed with a sgRNA but rather than mutating genomic 
loci, it occupies genomic sites (reviewed by Wang et al. [48]). 
In CRISPRi, dCas9 is covalently bound to a repressor domain, 
such as KRAB, resulting in transcriptional repression of the 
target gene by the promotion of heterochromatin at the 
promoter [49, 50]. Conversely, CRISPRa results in transcrip-
tional activation for overexpression of genes. This can be 
achieved through multiple approaches including the fusion 
of VP64, p65 and RTA [51]. CRISPRi is similar to RNAi in 
that it causes knockdown however currently, no CRISPRi 
screens have been used to investigate virus–host interactions. 
Likewise, CRISPRa may be likened to the overexpression 
screening as it results in an upregulation of gene expression 
whilst enabling overexpression of large genes to occur in a 
pooled format.
Using pooled CRISPR/Cas9 screening to identify 
antiviral factors
CRISPR/Cas9 screening to study virus–host interactions has 
primarily been performed in a pooled format. For example, 
Richardson et al. carried out a pooled screen to investigate 
ISGs implicated in the innate immune response to flavivi-
ruses [52]. Using the Brunello genome- wide knockout library, 
interferon alpha- inducible protein 6 (IFI6) was identified as 
an ISG responsible for inhibiting yellow fever virus (YFV) 
upon pre- treatment with IFN. MAGeCK was used to identify 
Fig. 2. Different approaches to CRISPR/Cas9 screening based on Cas9 variation. In CRISPR/Cas9 KO screens, a single guide RNA 
targets the Cas9 endonuclease protein to a specific locus in the coding sequence of a gene leading to a double strand break in the 
DNA. This activates the cellular DNA damage response; primarily, the imprecise non- homologous end- joining pathway that introduces 
INDELs resulting in gene knockout. For CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) screens, fusion of either a 
transcriptional activator or repressor domain to a catalytically inactive Cas9 subunit results in overexpression or inhibition of gene 
expression, respectively. Created with biorender.com.
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three significantly enriched sgRNAs, IFI6, signal transducer 
and activator of transcription 2 (STAT2) and interferon regu-
latory factor 9 (IRF9), these results were validated through 
individual knockouts. IFI6 was also ectopically expressed, 
with the results demonstrating that the absence of IFI6 
permits viral infection and its presence significantly restricts 
it. Hits were further shown to be antiviral against additional 
flaviviruses; West Nile virus (WNV), dengue virus (DENV) 
and zika virus (ZIKV) [52]. This is unlike many pooled virus–
host interaction screens that use survival screens to identify 
proviral factors.
CRISPR/Cas9 screening has been applied to identify host 
factors involved in severe acute respiratory syndrome corona-
virus 2 (SARS- CoV-2) pathogenesis, the virus responsible for 
the global COVID-19 pandemic that emerged in 2019. Given 
the nature of global pandemics, the need to rapidly identify 
host- dependency and antiviral factors that have the potential 
to be exploited is crucial. At the time of writing, at least three 
independent screens have been performed and two of which 
have tested small molecule inhibitors against candidate genes. 
Wei et al. performed a genome- wide screen in Vero- E6 cells 
using an African Green Monkey library, used due to their 
susceptibility to SARS- CoV-2 infection, to successfully iden-
tify genes resulting in both resistance and sensitisation to 
virus- induced cell death [53]. Three of the most highly ranked 
antiviral genes identified by the screen are components of the 
histone H3.3 chaperone complex. An independent genome- 
wide screen using the GeCKOv2 library was performed by 
Daniloski et al. in A549 cells constitutively expressing the 
angiotensin- converting enzyme 2 (ACE2) receptor [54]. 
Several sets of related genes were identified including four 
members of the endosomal protein sorting Retromer complex 
and four members of the endosomal trafficking Commander 
complex. Further gene set enrichment analysis established 
endosomal regulation and function as a consistent theme 
within candidate genes. Both studies subsequently tested small 
molecule inhibitors against a selection of candidate genes. 
Wei et al. identified three molecules that inhibit SARS- CoV-2 
replication and virus- induced cell death and Daniloski et al. 
identified seven inhibitors that resulted in more than 100- fold 
reduction of viral load with combinatorial therapy with small 
molecule inhibitors showing an additive effect in protection 
against SARS- CoV-2 infection. A third screen by Hoffmann 
et al. [55] used a focused screen established from previously 
reported SARS- CoV-2 protein interactors [56]. Using this 
focused screen, they identified host factors that promote and 
antagonise SARS- CoV-2 and three related coronaviruses at 33 
and 37 °C, the biological temperatures of the upper and lower 
respiratory tracts respectively. A number of genes implicated 
in promoting SARS- CoV-2 infection, including Rab GTPases, 
and antagonising virus induced cell death, including mamma-
lian mitochondrial ribosomal small subunit (MRPS) genes, 
were identified. The use of both genome wide and focused 
screening has therefore identified sets of genes, alongside 
individual genes, implicated in affecting the pathogenesis of 
SARS- CoV-2, something that may have otherwise not been 
identified in single- gene studies. In a situation requiring fast 
and actionable results, particularly in identifying therapeutic 
targets, high- throughput screening has provided a means to 
do so through providing targets for the repurposing of current 
pharmacological molecules.
CRISPR/Cas9 loss-of-function screening provides a 
synergistic view of HIV-1 infection
Many screens, and previous reviews, have focused on 
virus–host interactions upon infection with flaviviruses 
[18, 52, 57–60]. However, a multitude of other viruses have 
also been investigated including human immunodeficiency 
virus type 1 (HIV-1). Screens to investigate the interplay 
between host genes and viruses have identified various aspects 
of infection, including host dependency, antiviral and latency 
promoting factors.
Different cell lines have been utilised to study various aspects 
of HIV-1 infection. Park et al. performed the first genome- 
wide CRISPR/Cas9 screen in a CD4+ T cell line model to 
identify HIV-1 host dependency factors due to its suscepti-
bility to HIV-1 infection [61] whilst Rathore et al. used the 
J- Lat 10.6 cell line to identify novel latency promoting factors 
in HIV-1 infection [62]; a model Jurkat T- cell- derived cell 
line used as a model for HIV-1 latency, containing a single 
integrated, replication- incompetent HIV-1. Both screens used 
a green fluorescent protein (GFP) reporter for virus infec-
tion. Host dependency factors were identified by Park et al. 
by isolating GFP- negative cells upon transduction of cells 
with a custom sgRNA library, subsequently identifying five 
significantly enriched genes; CD4, CCR5, TPST2, SLC35B2, 
and ALCAM. In the virus latency study conducted by Rathore 
et. al, GFP expression correlated to HIV-1 reactivation and 
replication. Alternatively, GFP- positive cells were sorted by 
FACS for sgRNA enrichment analysis by MAGeCK resulting 
in fifty- two latency- promoting genes being selected for 
further validation. Host dependency hits were validated by 
single cell knockout with the loss of either TPST2 or SLC35B2 
conferring lack of viral entry which was restored upon the 
reintroduction of each gene. Latency promoting factors were 
validated using small molecule inhibitors, characterising the 
role of 26S proteasome non- ATPase regulatory subunit 1 
(PSMD1) in HIV-1 latency through reactivation of HIV-1 
infection following treatment.
To investigate antiviral factors targeting HIV-1, Ohainle et 
al. developed a human ISG CRISPR/Cas9 knockout library 
targeting approximately 2000 antiviral genes with sgRNAs 
sourced primarily from existing libraries [63]. It was first 
used alongside a custom vector in a CRISPR/Cas9 knockout 
screen to identify HIV-1 restriction factors. Ohainle et. al 
modified the lentiCRISPRv2 vector to maintain a complete 
HIV-1 LTR (HIV- CRISPR), maintaining the transcriptional 
and packaging competency of the vector whilst also deliv-
ering Cas9 and the sgRNA. Consequently, sgRNAs targeting 
antiviral genes were enriched in the viral supernatant due to 
increased viral replication in knockout cells. The screen was 
performed in zinc- finger antiviral protein (ZAP) knockout 
cells to increase screen performance as it had been suggested 
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that ZAP inhibited packaging of the HIV-1- CRISPR vector 
in viral particles, due to the high GC dinucleotide content of 
the HIV-1- CRISPR genome, therefore reducing the release 
of HIV-1- CRISPR virions. Genes including IFN-α receptor 
subunit 1 (IFNAR1), STAT1, IRF9, MxB, IFITM1, Tetherin 
and TRIM5α were identified but it was suggested that rather 
than a single ISG having a dominant effect, the cumula-
tive effect of multiple ISGs contributes to the restriction of 
HIV-1 replication. Ohainle et al. subsequently repeated the 
screen with different isolates of HIV-1 and demonstrated 
strain dependency of ISGs [63]. Results of the investigation 
looking at different HIV-1 isolates are consistent with those 
of Schoggins et al. and the generally accepted view of how 
IFN- dependent antiviral restriction operates [23]. Statistical 
analysis of enriched sgRNAs identified ISGs with modest anti-
viral phenotypes enabling recapitulation of patterns observed 
with overexpression screening. This shows the power of 
genome- wide CRISPR/Cas9 knockout screening in answering 
fundamental questions about the antiviral response.
As has been shown, many factors are able to help guide the 
design of a CRISPR/Cas9 screen and direct the outcome of 
results. Factors including library choice, cell line and vector 
can be manipulated to study different aspects of virus–host 
interactions highlighting the diversity and flexibility of the 
technique. Various aspects of the interplay between virus 
and host have been identified using varying experimental 
protocols which together provide a more rounded picture of 
the virus- host interactions during infection.
OVEREXPRESSION SCREENING
Overexpression screening allows for the characterisation 
of genes through observing how enhanced expression of a 
gene affects phenotype. The development of an ISG lentivirus 
library, consisting of 389 different ISGs, by Schoggins et al. 
in 2011 enabled the identification of antiviral factors, and 
their effects on viral replication, through overexpression of 
these ISGs in cells infected with a virus [23]. In an arrayed 
format, cells are transduced with a lentiviral vector, resulting 
in ISG- TagRFP expressing cells before being infected with 
GFP- expressing virus. Quantification of viral replication is 
performed using FACS by gating the TagRFP- positive popu-
lation and determining the number of green fluorescence 
protein positive (GFP+) cells in this sub- population [23].
The current ISG overexpression screening platform is not able 
to distinguish regulatory from direct antiviral ISGs. In order 
to overcome this and distinguish between ISGs that have a 
regulatory function and those that act directly on a virus, 
Kane et al. used an interferon- stimulated response element 
(ISRE) driven reporter cell line. This enabled directly acting 
ISGs to be identified as they would not activate the reporter, 
unlike transcriptional regulators such as IFN regulatory factor 
1 (IRF1) and toll- like receptor 3 TLR3. This reporter activity 
was measured soon after transduction to minimise indirect 
effects [64]. It is also vital in overexpression screening to 
ensure that the phenotypic effect is a result of the overex-
pressed ISG and not additional ISGs induced as a result of 
transduction and/or infection. This is resolved with the use 
of STAT1- deficient cells and upon investigation of varying 
cell types, Schoggins et al. showed that STAT1- deficient fibro-
blasts exhibited the highest levels of transduction compared 
with other cell types [23]. Similarly, a recent publication 
described using an arrayed ISG overexpression library to 
identify antiviral factors that inhibit human cytomegalovirus 
(HCMV) by performing parallel screens in human primary 
fibroblast cells and IRF3- deficient fibroblast cells [65]. IRF3- 
deficient cells provided confidence that the ISGs identified 
were specific against HCMV and not produced as a result of 
non- specific activation of IFN signalling. This further enabled 
identification of previously unknown IRF3- dependent ISGs. 
Using this method they were able to identify TRIM25 and 
ZAP as HCMV inhibitors amongst other proteins [65].
Identifying restriction factor patterns with 
comparative overexpression screening
Multiple studies have used ISG overexpression screening in 
a comparative manner to investigate differences in antiviral 
effectors between viruses, either between virus families or 
within the same family. Schoggins et al. investigated ISG inhi-
bition patterns across viruses from three families and identi-
fied broad- acting inhibitors, such as IRF1, alongside specific 
inhibitors. In the same study a predominant additive antiviral 
effect of ISGs was identified through varying combinatorial 
pairing of hits from the primary ISG screen [23].
In 2014, further comparative ISG analyses were carried out 
on 13 diverse viruses comprising of six negative- sense single 
strand RNA (−ssRNA) viruses and seven positive- sense single 
strand RNA (+ssRNA) viruses [66]. Hierarchical clustering 
analysis was performed using R statistical software for viruses 
screened in STAT1−/− fibroblasts, thus ruling out the potential 
complication of endogenously expressed ISGs as a result of 
transduction and/or infection. Infectivity of the 13 viruses 
was assessed in cells overexpressing 22 ISGs and the subse-
quent hierarchical clustering analysis grouped viruses and 
ISGs to graphically show either hierarchical relationships or 
similar ISG effects on virus infectivity via dendrograms or 
heatmaps respectively. Results revealed two clusters corre-
sponding to −ssRNA and +ssRNA viruses, indicating that 
related viruses are targeted by similar ISGs. Sub- clusters 
formed between more phylogenetically similar viruses; for 
example, within the −ssRNA cluster, a sub- cluster containing 
respiratory syncytial virus (RSV), human metapneumovirus 
(HPMV), parainfluenza virus subtype-3 (PIV3) and measles 
virus (MeV) is formed. It is unsurprising that similar ISGs 
are antiviral against these viruses given that RSV and HPMV 
are both Pneumoviruses whilst PIV3 and MeV are both 
Paramyxoviruses, two families that were only taxonomi-
cally separated in 2016 [67]. Similar to the −ssRNA viruses, 
predicted clustering is seen in the +ssRNA viruses with YFV 
and WNV, both flaviviruses, showing strong similarity. Addi-
tional hierarchical clustering identified the same pattern of 
negative and positive- sense clusters; the top 30 hits identified 
in the primary screen were stated as present or absent for the 
selected 12 viruses and the binary values were subsequently 
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analysed using the MATLAB Statistics Toolbox. This observa-
tion was only possible due to the adaptability of overexpres-
sion screening to be used to investigate different viruses.
Overexpression screening using human and 
macaque ISG libraries
In 2016, the original overexpression library, consisting of 
389 different ISGs, was expanded to include a library of 
ISGs from Rhesus macaques [64]. Combined, this library 
constitutes 488 different ISGs, with 252 genes having both 
human and macaque variants. For comparison, the CRISPR/
Cas9 ISG library contains approximately 1900 genes [63]. This 
combined human–macaque library was further expanded in 
2019 by Rihn et. al to exceed 500 and 300 ISGs from humans 
and macaques, respectively [68]. Many overexpression screens 
have taken the approach to use the combined human and 
macaque ISG library despite investigating human pathogens.
Feng et al. used a flow cytometry gain- of- function screen 
to investigate ISGs involved in restricting early stages of the 
life cycle of the Bunyamwera orthobunyavirus (BUNV), the 
prototype virus of the larger Bunyaviridae order [69]. Cells 
overexpressing a combined human and macaque library [64] 
were infected with GFP- expressing BUNV (BUNV- EGFP). 
Subsequently, 20 inhibitory ISGs were identified, with the 
expression of nine human and five macaque genes reducing 
BUNV- EGFP titre by more than five- fold compared with the 
empty vector control. Of the 20 hits, 13 genes had isoforms 
in both libraries, thereby validating the use of macaque genes 
in investigating the human immune response. The inhibitory 
capabilities of these genes, both human and macaque ortho-
logues, were tested against 15 different bunyaviruses from 
four different families, including both clinical and agricultural 
pathogens. Despite divergent effects of the ISGs between 
bunyaviruses, fold inhibition of viruses by the human and 
macaque orthologues remained similar. IFN stimulated gene 
20 (ISG20), a well- documented antiviral protein against many 
different viruses [70], was one of the genes validated. Both 
the human and macaque orthologues of ISG20 significantly 
inhibited at least 9 of the 15 viruses by varying amounts. The 
observed varying activity between the human and macaque 
ISG20 orthologues, also seen in the BUNV fold inhibition 
rankings of the other 19 hits, may indicate that non- human 
isoforms have divergent anti- bunyaviral specificities. This 
species- dependent variation in ISGs had previously been 
identified by Kane et. al when testing the antiviral activity 
of ISGs against 11 different retroviruses with more than one 
third of hits identified present only in the macaque library 
[64].
Without screening, and the availability of both a human and 
macaque library, orthologues with similar antiviral capa-
bilities would not have been identified. This is important 
as the use of dual screening libraries may not only identify 
additional antiviral proteins but provide potential insights 
into the differences in the IFN response between species that 
may aid or protect against zoonotic transmission of viruses. 
Sequence differences in the macaque render some virus 
countermeasures ineffective. This approach may therefore be 
able to identify ISGs that are countered by the virus.
RNAI SCREENING
RNA interference (RNAi) was first discovered in Caenorhab-
ditis elegans in 1998 [71] and was first used for genome- wide 
screening in 2008 to investigate host dependency factors for 
influenza virus replication [72]. Since then, it has been used 
to investigate fields including cancer biology and signal-
ling alongside infectious disease, encompassing virus–host 
interactions. Such studies have been carried out in vitro in 
mammalian cell culture systems and in vivo in model organ-
isms, including mice and Drosophila melanogaster (reviewed 
elsewhere [73, 74]). The performance of RNAi screening 
across multiple organisms is enabled due to the conserved 
nature of the RNAi system across most eukaryotes. In brief, 
RNA constructs termed small interfering RNA (siRNA) 
or short hairpin RNA (shRNA) are introduced into cells, 
resulting in the silencing of target genes by degrading mRNA 
transcripts in the cytoplasm. shRNA, following processing 
by Drosha, is exported to the cytoplasm to be processed by 
Dicer, an endoribonuclease, to produce siRNA. This is then 
loaded into the RNA- induced silencing complex (RISC) and 
the siRNA–RISC complex can cleave complementary mRNA. 
siRNA is synthetically synthesised and can be directly trans-
fected into the cytoplasm, therefore bypassing processing 
steps, to be directly loaded into the RISC (reviewed [74, 75]).
Inconsistencies within RNAi screening
Many arrayed siRNA screens have been performed to iden-
tify host factors (HFs) that contribute to viral infection and 
multiple RNAi screens investigating the same virus have high-
lighted a lack of overlap in hits identified. Aydin et. al identi-
fied HFs required for human papilloma virus type 16 (HPV16) 
infection using pseudoviruses, which allowed them to focus 
on viral entry, but of the 162 HF hits identified, only four 
overlapped with the 261 hits previously identified by Lipovsky 
et. al to contribute to HPV16 infection [76, 77]. Similarly, 
Beard et. al identified factors that influenced vaccinia virus 
(VACV) replication, both proviral and antiviral, and when 
hits were compared with two previous VACV RNAi screens, 
no hits were identified in all three studies [78–80]. A study 
investigating host factors involved in Paramyxoviridae and 
Pneumoviridae life cycles showed discrepancies in identified 
hits dependent on the analysis tools used [81]. Independent 
screens were performed on MeV, mumps virus (MuV) and 
human respiratory syncytial virus (hRSV) and the data was 
subsequently analysed via different methods; meta- analysis 
approaches through ranking of z- scores and a bioinformatics 
approach using the Kolmogorov–Smirnov test. Of the 42 
proviral genes that overlapped between all three viruses as 
identified by complementary meta- analysis, only 24 of these 
were also identified by the bioinformatics package.
Additionally, multiple screens have been performed to iden-
tify host factors required for HCV infection. Studies have 
investigated different stages of the viral lifecycle through use 
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of different experimental systems. Tai et al. [82] and Ng et al. 
[83] used a replicon system enabling identification of host 
factors implicated in virus replication whilst Li et al. [84] used 
an infection competent HCV cell culture system (HCVcc) 
enabling investigation of all stages of the viral lifecycle. Little 
overlap in hits was seen between the two screens and the 
differences in study design may have contributed to this. The 
replicon systems used in these studies were not analogous as 
Tai et al. used a replicon encoding viral proteins NS3 to NS5B 
and a firefly luciferase reporter [82] whilst Ng et al. used a 
replicon system with a secreted alkaline phosphatase (SEAP) 
reporter [83]. Both replicon screens identified SLC12A5 as a 
hit, however, Tai et al. used a liver cell line and this gene is a 
neuron- specific transcript leading to the assumption the gene 
was a false positive caused by off- target effects in more than 
one screen [82]. Another genome- wide screen was performed 
by Fusco et. al to identify IFN effector genes that inhibit HCV 
[85]. Of the candidate genes identified, only 52 % of the hits 
had previously been shown to have antiviral activity, with 
only 8 % previously having been described as having antiviral 
activity against HCV. The use of pseudovirions expressing 
HCV glycoproteins identified four antiviral genes (DPP4, 
MYST1, PPP3CB and SLC7A2). Four genes (ALG10, DPP4, 
PPP3CB and PDIP1) were also found to restrict viral replica-
tion by using HCV full genome OR6 replicons.
Results from previous studies have indicated that the lack 
of overlap in candidate genes between screens of the same 
virus is due to differences in screening methodology [82]. 
However, results from additional studies indicate that even in 
the absence of screening differences, the choice of analysis can 
be enough to influence identified hits, therefore contributing 
to inconsistencies in results – a phenomenon that may also 
be present in CRISPR/Cas9 screening analysis. Alternatively, 
despite the lack of overlap in individual genes between studies, 
bioinformatics analysis is able to identify conserved pathways 
between hits in different screens [76]. For example, nuclear 
pore proteins have been identified as HFs in multiple RNAi 
screens investigating VACV, indicating their role in Poxvirus 
infection [78]. This may indicate a role for comparative RNAi 
screening in understanding the broader picture of virus–host 
interactions.
RNAi screening identifies antiviral factors 
restricting flavivirus replication
Alongside the popularity of CRISPR/Cas9 screens for inves-
tigating flavivirus restriction factors, RNAi screening has also 
been performed to identify restriction factors against this 
family of viruses. Following a genome- wide siRNA screen to 
identify antiviral factors restricting influenza A virus (IAV) 
infection, IFITM proteins were identified as hits [86]. These 
were subsequently tested against several flaviviruses; WNV, 
YFV and Omsk haemorrhagic fever virus (OHFV). Using 
virus- like particles expressing the envelope proteins of each 
respective virus, IFITM1, IFITM2 and IFITM3 were all able 
to inhibit infection compared with controls. IFITM3 was vali-
dated as a flavivirus antiviral factor upon infection with path-
ogenic WNV and DENV-2. Stable overexpression and siRNA 
knockdown of IFITM3 resulted in significantly decreased and 
increased viral replication, respectively. More recently, Li et 
al. used an ISG specific library to investigate WNV restriction 
factors [87]. Adapted from microarray studies, the ISG library 
contains shRNA against 245 genes. The shRNA is cloned 
into a lentiviral vector containing a GFP reporter. Following 
successful transduction, the cells are then challenged with 
a red fluorescent protein (RFP)- expressing virus similar to 
the overexpression screening method [87]. Using the ISG- 
specific library, thirty ISGs were identified whose knockdown 
significantly increased infectivity. These hits were validated 
through ectopic gene expression. Genes such as IFI6 were 
shown to restrict viral replication, an expected result as IFI6 
has been shown to be widely antiviral. IFI6 has subsequently 
been shown to be a flavivirus restriction factor by Richardson 
et al. using a CRISPR/Cas9 screen [52]. IFITM3, an antiviral 
factor previously identified by Brass et al. to restrict WNV 
and DENV-2 infection [86] was not identified as a hit using 
the ISG library. However, Li et al. subsequently showed 
that IFITM3 was able to to restrict WNV when ectopically 
expressed. This reaffirms the need for independent valida-
tion of hits due to inconsistency between screen designs and 
resulting antiviral factors identified. An interesting finding by 
Li et al. was the identification of a regulator of cellular gene 
expression; activating signal cointegrator 1 complex subunit 3 
(ASCC33) [87]. Overexpression of the gene increased WNV 
replication whilst silencing decreased replication through 
the upregulation of multiple antiviral ISGs, the inverse effect 
seen with other ISGs. It was suggested that following IFN-β 
induced expression of ASCC33, ASCC33 modulates the 
activity of IRF-3 and IRF-7 pathways to dampen ISG expres-
sion. Among ISGs there are proviral and antiviral factors, 
however, during screening using a genome- wide library, 
genes permitting virus replication are often classed as host 
dependency factors whilst genes restricting virus replication 
are termed antiviral factors. Overexpression of ASCC33 
results in a host dependency factor- like phenotype, however, 
by narrowing the library to ISGs only, it was instead revealed 
to be a modulator of the IFN response.
CHOOSING A SCREENING METHOD
Advantages and disadvantages of screening 
techniques
Advances in molecular tools, such as the development of 
NGS for sequence- based analysis, have enabled forward 
genetic screening to become easier. These advances are 
therefore imperative as the success of forward genetics relies 
on the ability to characterise genes resulting in the desired 
phenotype. For the three screening methods discussed, there 
are advantages and disadvantages to each (summarised in 
Table 1) and many other pitfalls are due to mechanistic details 
of the methods previously mentioned (reviewed elsewhere 
[23, 37, 74, 75, 88]). The decision of what screen to use for an 
investigation may therefore be influenced by what the screen 
is able to achieve.
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A large influencing factor for screening is the range of the 
available libraries. The library of the overexpression screening 
described currently is limited to ISGs [2], and is therefore 
limited to investigating antiviral factors whilst CRISPR/
Cas9 and RNAi screening are also able to identify novel host 
dependency factors. Conversely, the overexpression library 
has the benefit of possessing a combined library of human 
and macaque genes for comparative studies [64]. Likewise, 
although this review focusses on RNAi screening in mamma-
lian cell culture systems, there are well established libraries 
and protocols for RNAi screening in Drosophila [89]; an 
advantage over other screening.
A widely accepted caveat with RNAi based screening is the 
presence of off- target effects (OTEs) [90] which fall into 
three categories; OTEs caused by siRNA sequence similarity 
[91, 92], OTEs caused by microRNA (miRNA) like events 
[93, 94] and sequence independent OTEs [95]. The resolution 
of this problem is important in screening as both false nega-
tive and false positive results lead to reduced reproducibility 
between RNAi screens [96]. OTEs caused by siRNA sequence 
similarity occur when a siRNA sequence is too similar to an 
unrelated messenger RNA (mRNA). Whilst most siRNAs are 
21–23 nt [74], a 19- mer rule has been established to counter 
this. It has been shown that a 19 nt siRNA is sufficient to 
result in gene knockdown. However, to reduce the likelihood 
of OTEs, the 19- mer must not show any sequence similarity 
with any other mature gene transcript [74, 97]. Additionally, 
most siRNA libraries contain at minimum three siRNAs per 
gene and in most studies a hit is only considered when two or 
more of these give rise to a result that is two to three standard 
deviations away from the sample set mean [98, 99].
OTEs caused by miRNA- like events occur due to the shared 
downstream effector, Ago, of siRNAs and miRNAs. Whilst 
complete complementarity of an siRNA to target sequence 
results in on- target cleavage, partial pairing due to high 
complementarity of the seed sequence with the target sequence 
[100], which is observed in miRNA–target interactions in 
animals, results in unintended miRNA- like OTEs with the 
use of siRNAs [101]. Unfortunately, unlike siRNA similarity, 
this is a harder obstacle to overcome when designing siRNAs 
for screening. The last category of OTEs are sequence- 
independent events. It has been found that siRNAs are able 
to activate the type I IFN response in a sequence- independent 
manner [95]. RNAi screens can also be performed using 
dsRNA however this is not used in mammalian cell screens 
as dsRNA is a PAMP that is recognised and subsequently acti-
vates IFN induction [102]. CRISPR/Cas9 screening displays 
a reduced immune response compared with RNAi screening 
due to a reduced susceptibility to OTEs.
Multiple developments have been made in the design of 
sgRNAs for CRISPR/Cas9 screening to reduce the likelihood 
of OTEs and increase target specificity [45, 47, 103, 104]. 
In comparison, overexpression screening does not require 
constructs for the knockdown or knockout of genes. This 
therefore removes the obstacle of hits produced as a result 
of OTEs in the screen. An important distinction to be made 
between RNAi and CRISPR/Cas9 screening is the duration 
of genetic modulation and the point in the cell at which each 
technology targets. Genetic modification of genes by Cas9, 
rather than dCas9, results in the permanent targeting of 
genes at the DNA level [35] whilst RNAi results in a tran-
sient reduction in gene levels at the mRNA level [105]. This 
means protein expression can be restored in the cell, allowing 
for validation of hits identified by RNAi screening [106]. 
However, a limitation to this transient knockdown of mRNA 
is the incompleteness of gene knockdown. In a comparison 
of a CRISPR GeCKO screen, with six sgRNAs per gene, and 
a shRNA screen, with four shRNAs targeting each gene, the 
Table 1. Summary table of advantages and disadvantages for each of the three screening methods discussed; CRISPR, RNAi and overexpression 
screening
Advantages Disadvantages
CRISPR/Cas9 Permanent targeting of genes for robust response.
Ability to multiplex.
Ease of construction.
Adaptability of 20 bp protospacer.
Target specificity.
Eliminates confounding effects from low level protein expression.
Use of dCas9.
Reduces activation of innate immune response compared with RNAi.
Well established in mammalian cell culture.
Cannot be used to study essential genes.
Relies on Cas9 expression levels.
Requires selection step.
Difficult to identify moderately acting antiviral factors.
Off- target effects.
Redundancy.
RNAi Ability to investigate essential genes.
Ability to restore protein expression for validation.
Reagents readily available.
Well established in mammalian cell culture, mice, and Drosophila models.
Off- target effects and high rate of false- positives.
Low percentage of reproducible hits.
Inability to knockdown non- coding regions.
Incompleteness of gene knockdown.
Longer siRNAs can trigger the immune response.
Redundancy.
Overexpression Combined species libraries (human and macaque).
Suitability for arrayed comparative screening.
Library limited to ISGs.
Able to identify moderately acting antiviral factors.
Dependent on producing high lentiviral stocks.
ISG- mediated and overexpression artefact toxicity.
Requirement for fluorescence readout.
Requirement for automation of equipment.
Cannot identify proteins that function in a complex.
‘Long genes’ more difficult to handle.
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shRNA screen showed incomplete knockdown of fluorescence 
whilst the GeCKO screen resulted in 93 % of cells showing no 
fluorescence [107]. A further consequence of acting at the 
mRNA level is also the inability to knockdown non- coding 
regions, unlike CRISPR/Cas9 screening [108]. There is also a 
desire to perform these screens in primary mammalian cells 
due to their increased physiological relevance. However, due 
to the limited time- span these cells can be cultured for, there 
are difficulties surrounding screening which, from editing 
to analysis, can often be lengthy. Transduction of primary 
cells is often difficult with low resulting transduction rates 
meaning perturbational studies, such as RNAi, and CRISPR/
Cas9, involving lentiviral transduction, are more difficult than 
in cultured cell lines [109, 110]. Additionally, cell viability 
or growth screening, as is often the case with CRISPR/Cas9 
screens, is difficult. Alternative cellular markers or FACS- 
based phenotypic selection, as shown with primary T- cells, 
may be used instead. There are advantages to using both 
immortal and primary cell lines during screening. Immortal 
cell lines have a less limited passage number, allowing for a 
growth- based phenotypic readout, whilst primary cells can 
be used to identify critical signalling pathways or effector 
functions. For example, morphological or functional differ-
ences in human immune cells may result in unidentified 
pathways if other cell lines are used. It has been suggested 
that for some genes, knockdown of a gene by shRNAs or 
siRNAs may result in an alternative or reduced phenotype 
compared with complete knockout [111, 112]. Therefore, if 
performing a positive selection screen and sorting cells with 
FACS, of which only the extreme phenotypes are selected for, 
knockdown may cause significant results to be missed [113]. 
A knock- on effect of this is the strength of antiviral factors 
each screen can identify. Knockdown, as a result of RNAi, is 
incomplete and so may not be able to identify moderately 
acting antiviral factors whereas overexpression and CRISPR/
Cas9 screening, which results in complete knockout, have a 
greater capacity to identify moderate antiviral factors or those 
that work in combination with others [63].
Limitations of overexpression screening remain the difficulty 
in identifying proteins that function in a complex and the 
cost of generating libraries. The overexpression of a single 
subunit may not evoke a phenotypic result and so factors 
may be missed; this is an issue knockout screens are able to 
overcome. Equally, CRISPR/Cas9 and RNAi screening may 
be insufficient when trying to investigate redundant factors 
or when investigating antiviral factors that target a virus not 
susceptible to IFN due to the reliance on extreme phenotypes 
for the identification of hits. If more than one gene product 
restricts infection, ‘deleting’ only a single gene will be pheno-
typically silent or the effect will be so minimal that the cell is 
not selected for further processing.
If a virus has reduced susceptibility to IFN, it is more diffi-
cult to discern functionally redundant ISGs from ISGs with 
a moderate effect due to the vast number of ISGs expressed. 
This is because the difference in phenotype compared with 
the control, or ‘window of identification’, is reduced. As 
overexpression screening does not rely on the restoration of 
infection, it is better equipped to identify ISGs of moderate 
effect. By broadening the window of identification, it would 
be possible to increase the number of moderately acting 
antiviral factors identified in CRISPR/Cas9 screening. One 
possibility might be to use cells deficient in IFN stimulated 
gene 15 (ISG15); these cells, when treated with IFN-α, exhibit 
an overamplified IFN response resulting in the overexpres-
sion of ISGs and, subsequently, a greater ability to resist virus 
infection. Holthaus et al. confirmed that virus resistance in 
ISG15−/− cells was due to the overexpression of viral restric-
tion factors [114]. Because cells are resistant to infection, they 
are phenotypically silent and not detectable by FACS when 
infected with a reporter virus; deletion of a restriction factor, 
even one with low to moderate activity, results in a detect-
able signal that would be otherwise missed. For example, 
previously published work has indicated that IFIT1 modestly 
inhibits human parainfluenza virus type 2 (hPIV2) protein 
expression, at least in cell- free assays [115]. Despite this, in an 
infection model (as would be used in a screening protocol), 
IFIT1- deficient cells pre- treated with IFN showed levels of 
viral protein expression not overtly different from IFN- pre- 
treated control cells. However, when IFIT1 was knocked down 
in ISG15−/− cells, hPIV2 protein expression was significantly 
higher compared with IFN- treated ISG15−/− cells with intact 
IFIT1 expression, indicating that IFIT1 does indeed play an 
antiviral role, albeit with low to moderate activity, against 
hPIV2 [114]. Such conclusions could not be made without 
expanding the ‘window of identification’. Nonetheless, posi-
tive selection CRISPR/Cas9 screens cannot be used to study 
essential genes, as knockout of the genes is lethal to the cell, 
therefore removing them from the set of genes subsequently 
analysed [13, 42, 43].
Both RNAi and CRISPR/Cas9 screening libraries and reagents 
are readily available, however, the adaptability and ease of 
construction of the 20 bp protospacer enable a greater flex-
ibility in designing custom CRISPR/Cas9 libraries [116, 117]. 
Despite this, both overexpression, CRISPR/Cas9 and RNAi 
screening, if using shRNA, primarily rely on the production of 
lentiviral stocks and efficient transduction into cells. CRISPR/
Cas9 screening further relies on Cas9 expression levels in the 
cell if a single transduction vector is not used [118].
Despite the advances in gene perturbation screening since 
its development, there are still pitfalls associated with the 
bioinformatic analyses used to dissect such screens, not 
only limited to the technical noise generated by such a 
high- throughput technique. The popularity of CRISPR/
Cas9 screening is increasing at a faster rate than the devel-
opment of data analysis methods [119]. Currently there is 
no consensus bioinformatic analysis method of such screens 
with many algorithms being more suited to, or originally 
designed for, siRNA screens, RNA- seq and microarrays 
rather than CRISPR/Cas9 [120]. Despite this, MAGeCK, 
alongside other algorithms, have been developed specifically 
for analysis of CRISPR/Cas9 screens [121]. The large range 
of bioinformatic tools currently available results in varying 
modelling strategies, with different strengths and weak-
nesses, being utilised between analyses which users may be 
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unaware of [119]. Some analysis packages, such as CasTLE 
and BAGEL, require the input of gold standard genes (927 
non- essential genes derived from previous pooled screens) 
whilst others, such as MAGeCK, do not [122]. The required 
negative control has also been suggested to affect the presence 
of false positive hits in the bioinformatic pipeline; some strate-
gies and computational methods use non- targeting guides as 
negative controls in place of sgRNAs targeting non- essential 
genes. It has been suggested that the latter may result in fewer 
false positives [123]. Additionally, most algorithms designed 
to analyse CRISPR genes assume that most genes are non- 
essential. Whilst this does not appear to affect the results of 
large genome- wide screens it is currently not known what 
effect this has on the results of custom screens whose targeted 
genes are under selection [123]. As previously discussed, 
differences in the bioinformatic analysis of RNAi screens 
contributes to observed variance in hits [81] and the same 
phenomenon may be occurring during the bioinformatic 
analysis of CRISPR/Cas9 screens.
Using complementary approaches within screening 
studies for hit identification
As previously described, each of the screening methods 
discussed have their advantages and disadvantages. There 
are situations when a single technique cannot be used as 
results would be missed. There is therefore scope to use these 
techniques in a complementary fashion, to result in a more 
comprehensive picture of virus–host interactions.
Simultaneous RNAi and CRISPR/Cas9 screening has been 
used to investigate the effects of an antiviral drug and showed 
differences in significant hits [124]. Essential genes, such as 
those in the nucleotide biosynthesis pathway, were significant 
hits in the siRNA screen whilst a CRISPR/Cas9 screen identi-
fied others, such as those in mTOR signalling and regulation 
that are non- essential but require complete deletion. Kranz et 
al., although not investigating virus–host interactions, used 
a complementary approach to screening using both RNAi 
and CRISPR/Cas9 technology. Results of the primary screen 
identified FAT Atypical Cadherin 1 (FAT1) as having a role in 
apoptosis. This was independently tested using CRISPR/Cas9 
knockout and both approaches resulted in the same pheno-
type, validating the result [125]. Subramanian et al. used a 
complementary approach to investigate the antiviral action of 
Tudor domain- containing protein 7 (TDRD7) against Sendai 
virus (SeV). TDRD7 was identified as an antiviral factor 
following a shRNA screen using a library against human 
ISGs. Following knockdown of the gene by RNAi, validation 
of the hit and further characterisation of the resulting pheno-
type was performed by knocking out the endogenous gene 
using CRISPR/Cas9 and ectopically expressing an exogenous 
version of the gene [126].
In each of these examples, the use of two gene perturbation 
technologies within the same study allowed for independent 
validation of results and further characterisation of hits from 
primary screens. In these examples, CRISPR/Cas9 was used to 
validate RNAi hits, however, the reverse could be performed. 
The use of RNAi following CRISPR/Cas9 screening may allow 
for the strength of hits to be validated when comparing pheno-
types resulting from knockout and knockdown of the same 
gene. The use of RNAi in validating CRISPR/Cas9 screens 
may also determine if the resolution of a gene, as RNAi is 
temporary, reverses the observed phenotype back to wildtype.
OTHER APPROACHES
Techniques other than those discussed have also been used 
to study virus–host interactions. These include, data and 
literature mining, single- cell approaches and proteomics 
approaches. McDonald et al. curated a single combined data-
base of genes from published studies using omics approaches 
to investigate genes upregulated in response to RSV infec-
tion. From this database they identified genes present across 
studies and ranked them by factors including occurrence to 
generate a candidate list of genes to be validated [127]. The 
use of a literature- mining approach to generate a candidate 
list enables identification of gene overlap, a pitfall of some 
screening methods, to provide confidence in hits identified. 
Single- cell approaches have also been used to investigate host–
pathogen interactions. Single- cell RNA- seq (scRNA- seq) has 
been used to identify genes associated with latent HIV-1 
infection [128, 129]. Results indicated an increase in HIV-1 
suppressive genes, such as chemokine Ligand 3 (CCL3), and 
a decrease in IFN responsive genes, including STAT1, IFI6 
and ISG20. However, single- cell approaches are often limited 
to arrayed formats, resulting in reduced throughput. CRISP-
 seq, also referred to as CROP- seq and Perturb- seq, has been 
developed to encompass the resolution of RNA- seq and the 
high- throughput nature of pooled CRISPR/Cas9 screening 
[130–133]. This allows for a more detailed understanding 
of cellular interactions caused by perturbations outside of 
phenotypes such as cell survival. CRISP- seq has been used to 
investigate the effect of knocking out IRF9, a gene within the 
antiviral IFN response [133]. It was found that genes enriched 
for IRF9 knockout had a reduced antiviral response, including 
the genes IFIT2, CXCL10 and OASL1. This shows the power 
of using CRISP- seq to identify genes involved in regulating 
virus–host interactions. cDNA screening, although not 
predominantly used nowadays, is another gain- of- function 
screening method used to identify virus–host interactions; 
particularly useful for genes that require induction or are not 
ectopically expressed in the model cell line used [134]. cDNA 
libraries can range in size [135], for example, Nguyen et. al used 
a cDNA library of 15000 genes to identify proviral host factors 
for HIV- IIIb infection in HIV- permissive HeLaCD4βgal cells 
[136]. Subsequently, 315 HFs that increased infection were 
identified, including mixed lineage kinase 3 (MLK3).
Quantitative proteomics has also been used to identify anti-
viral proteins. Stable isotope labelling by amino acids in cell 
culture (SILAC), alongside other labelling methods such 
as tandem mass tagging (TMT) or label- free setups, can be 
used to compare virus and mock infected cells and identify 
differences in protein abundance between the two popula-
tions [137]. Nightingale et al. used a multiplexed proteomics 
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approach to identify HCMV restriction factors, including 
helicase- like transcription factor (HLTF). Proteins rescued 
by proteasomal and lysosomal inhibitors upon HCMV infec-
tion, compared with mock infected cells, were identified using 
TMT peptide labelling and mass spectrometry. Hits were then 
further investigated by pSILAC to look at the rate of protein 
turnover in HCMV and mock infected cells [138].
FUTURE PERSPECTIVES
Each of the screening techniques discussed has its place in 
investigating virus–host interactions both in the identifica-
tion of host dependency factors and antiviral factors. As these 
techniques are further developed, as already observed for ISG 
overexpression libraries and CRISPR/Cas9 library design, the 
power of these techniques will also increase.
A consequence of specific ISGs remaining unknown for 
most viruses is the resulting difficulty in investigating other 
components of the antiviral response. An exception to this 
is PIV5, where IFIT1 is known to be the primary restriction 
factor [139]. Recently, Holthaus et al. developed an infection 
model using this information to determine that PIV5 virus 
resistance is a result of direct antiviral activity [114]. There-
fore, a greater understanding of the antiviral response and the 
specific restriction factors involved, through high- throughput 
genetic screening, may allow investigation of the wider IFN 
response.
Genetic screens have also been developed to study pathogens 
of agricultural significance. Tan et al. have developed a bovine 
CRISPR/Cas9 knockout library, btCRISPRko.v1, consisting 
of 96 000 sgRNAs to identify genes involved in virus–host 
interactions. The btCRISPRko.v1 library has subsequently 
been used identify cellular factors involved in replication of 
bovine herpes virus type 1 (BHV-1), a virus that results in 
severe economic burden in the cattle industry, and resulted 
in the identification of over 150 proteins. The development 
of a bovine screening library will enable the investigation of 
virus–host interactions upon infection with other cattle path-
ogens [140]. Furthering our knowledge of not only bovine 
but other livestock diseases may help provide food security 
alongside aiding our understanding of zoonotic transmission 
as a barrier to zoonotic infection are the differences in host 
IFN response between species.
Currently, validation of RNAi screening results with replica-
tive CRISPR/Cas9 screening has been marginal and those 
that have been performed have seen minimal overlap in 
results. In future, it may be that the combination of various 
screening techniques to validate hits will enable greater 
overlap between studies of the same virus. However, 
problems are still associated with these screens, including 
the standardisation of screening results. As the number of 
published data sets from screening, in any form, increases, a 
more comprehensive picture of virus–host interactions can 
be established. As more screens are performed, it is likely 
that standardisation between data sets will improve, allowing 
for comparison between screens and the identification of 
common hits. This will enable greater confidence in hits 
and provide evidence for therapeutic targets. Additionally, 
increased comparative screens between viruses may result 
in hits that can be exploited as broad therapeutic targets. 
ISG- specific libraries are now available for all three screening 
techniques discussed [23, 63, 87] enabling targeted screening 
of antiviral restriction factors. Targeted validation screening 
of antiviral factors, rather than performing a genome wide 
screen, is therefore possible and greater overlap of hits may 
be observed.
The use of genetic screening to identify not only antiviral 
factors, but host- dependency factors, undeniably has its 
benefits. Without a sufficient number of hits being identi-
fied under the same experimental conditions, clustering 
analysis to this level would not be feasible. It is these analyses 
that provide greater insight than single- gene studies can 
provide into virus–host interactions. Similarly, the level of 
redundancy of the IFN response, identified through high- 
throughput screening itself, provides reasons for the need 
for these methods. Despite the caveats regarding these 
methods, they are a powerful tool for investigating virus–
host interactions.
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